An Evaluation of Orexin Receptor Agonists Versus Traditional Pharmacotherapy in Narcolepsy Type 1
TL;DR
It is found that OX2R agonists achieve single-agent efficacy for sleepiness and cataplexy but several issues, such as incomplete diagnostic criteria and persistent underdiagnosis, still constrain their clinical impact.
Abstract
Narcolepsy type 1 (NT1) is a chronic hypersomnia caused by autoimmune-mediated destruction of hypothalamic orexin (hypocretin) neurons, producing excessive daytime sleepiness (EDS), cataplexy (the loss of muscle control), and REM sleep intrusions. In the past 3 decades, the treatment has relied on symptomatic pharmacotherapy: wake-promoting agents for sleepiness, anti-cataplexy agents for REM-related symptoms, and traditional stimulants. However, neither restores orexin signaling itself. This paper reviews recent primary and secondary literature to compare traditional multi-drug regimens with the emerging class of orexin receptor 2 (OX2R) agonists, which act directly on the pathway the disease disables. It evaluates whether OX2R agonists represent a mechanistic advance over existing pharmacotherapy and what still limits their translation into standard care. Drawing on clinical trial data for 3 OX2R agonists (TAK-994, danavorexton and oveporexton) alongside pharmacotherapy reviews and diagnostic studies, the paper finds that OX2R agonists achieve single-agent efficacy for sleepiness and cataplexy but several issues, such as incomplete diagnostic criteria and persistent underdiagnosis, still constrain their clinical impact.